文献速递认知障碍与痴呆

客观记忆损害分期与认知正常个体中新发症状性认知损害的关联

Association of Stages of Objective Memory Impairment With Incident Symptomatic Cognitive Impairment in Cognitively Normal Individuals.
PubMed 文献 · Neurology · 2023-04-19

在969名认知正常(CDR=0)的Knight阿尔茨海默病研究中心参与者中,依据基线自由与线索选择性提醒测验确定SOMI分期,采用Cox比例风险模型分析SOMI分期与新发症状性认知损害(CDR≥0.5)的关联。结果显示SOMI-1与SOMI-2的临床进展风险接近无记忆问题者的两倍,SOMI-3/4约增加3倍,校正生物标志物后SOMI分期仍为独立预测因子。作者认为SOMI有助于识别最可能进展为症状性认知损害的认知正常个体以转诊进行生物标志物筛查。

要点

  • SOMI-1和SOMI-2期个体临床进展风险接近无记忆问题者的两倍。
  • 出现记忆存储损害(SOMI-3/4)时,临床进展风险约增加3倍。
  • 校正β-淀粉样蛋白、tau病理和神经退行性变生物标志物后,SOMI分期仍为独立预测因子。

核心结论

  • SOMI可预测从认知正常向新发症状性认知损害(CDR≥0.5)的转变。
  • 结果支持使用SOMI识别最可能发生新发认知损害的认知正常参与者,以便转诊进行生物标志物筛查。

研究设计与样本

  • 研究纳入969名认知正常(CDR=0)的Knight阿尔茨海默病研究中心参与者,依据基线自由与线索选择性提醒测验评分确定SOMI分期。
  • 其中555名有脑脊液和结构MRI测量数据,构成生物标志物亚组,该亚组中144名为淀粉样蛋白阳性。
  • 采用Cox比例风险模型检验基线SOMI分期和生物标志物与新发认知损害(定义为向CDR≥0.5转变)时间的关联。

主要发现

  • 全部参与者平均年龄69.35岁,女性占59.6%,平均随访6.36年。
  • 与SOMI-0(无记忆损害)相比,SOMI-1至SOMI-4参与者从正常向认知损害转变的风险比升高。
  • SOMI-1(轻度提取损害)和SOMI-2(中度提取损害)个体临床进展风险接近无记忆问题者的两倍。
  • 出现记忆存储损害(SOMI-3/4)时,临床进展的风险比约增加3倍。
  • 校正所有生物标志物后,SOMI分期仍为新发认知损害的独立预测因子。

关键数值与推荐

  • 症状性认知损害定义为临床痴呆评定量表(CDR)≥0.5。
  • 认知正常定义为CDR=0。
  • SOMI-1为轻度提取损害,SOMI-2为中度提取损害,SOMI-3/4为记忆存储损害。

临床怎么用

  • 作者认为结果支持使用SOMI识别最可能发生新发认知损害的认知正常参与者,以便转诊进行生物标志物筛查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Increasing evidence indicates that a subset of cognitively normal individuals has subtle cognitive impairment at baseline. We sought to identify them using the Stages of Objective Memory Impairment (SOMI) system. Symptomatic cognitive impairment was operationalized by a Clinical Dementia Rating (CDR) ≥0.5. We hypothesized that incident impairment would be higher for participants with subtle retrieval impairment (SOMI-1), higher still for those with moderate retrieval impairment (SOMI-2), and highest for those with storage impairment (SOMI-3/4) after adjusting for demographics and APOE ε4 status. A secondary objective was to determine whether including biomarkers of β-amyloid, tau pathology, and neurodegeneration in the models affect prediction. We hypothesized that even after adjusting for in vivo biomarkers, SOMI would remain a significant predictor of time to incident symptomatic cognitive impairment. METHODS: Among 969 cognitively normal participants, defined by a CDR = 0, from the Knight Alzheimer Disease Research Center, SOMI stage was determined from their baseline Free and Cued Selective Reminding Test scores, 555 had CSF and structural MRI measures and comprised the biomarker subgroup, and 144 of them were amyloid positive. Cox proportional hazards models tested associations of SOMI stages at baseline and biomarkers with time to incident cognitive impairment defined as the transition to CDR ≥0.5. RESULTS: Among all participants, the mean age was 69.35 years, 59.6% were female, and mean follow-up was 6.36 years. Participants in SOMI-1-4 had elevated hazard ratios for the transition from normal to impaired cognition in comparison with those who were SOMI-0 (no memory impairment). Individuals in SOMI-1 (mildly impaired retrieval) and SOMI-2 (moderately impaired retrieval) were at nearly double the risk of clinical progression compared with persons with no memory problems. When memory storage impairment emerges (SOMI-3/4), the hazard ratio for clinical progression increased approximately 3 times. SOMI stage remained an independent predictor of incident cognitive impairment after adjusting for all biomarkers. DISCUSSION: SOMI predicts the transition from normal cognition to incident symptomatic cognitive impairment (CDR ≥0.5). The results support the use of SOMI to identify those cognitively normal participants most likely to develop incident cognitive impairment who can then be referred for biomarker screening.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Grober E, Petersen KK, Lipton RB, et al. Association of Stages of Objective Memory Impairment With Incident Symptomatic Cognitive Impairment in Cognitively Normal Individuals. Neurology. 2023. PMID: 37076305. doi:10.1212/WNL.0000000000207276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。